Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Conditioning with TBI for Elderly Aplastic Anemia HSCT
NCT06769568Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of busulfan, fludarabine, cyclophosphamide and antithymocyte globulin rabbit in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Survival at 2 years. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
busulfanfludarabinecyclophosphamideantithymocyte globulin rabbit
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06769568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769568.